Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Evolus Inc (EOLS) today and set a price target of $35. The company’s shares opened today at $14.70.
Chen commented:
“Based on our diligence, dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market leader Botox sold at a discount. Therefore, we think Jeuveau could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $35 12-month price target.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 7.3% and a 38.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Evolus Inc has an analyst consensus of Moderate Buy, with a price target consensus of $30.
See today’s analyst top recommended stocks >>
Based on Evolus Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.83 million. In comparison, last year the company had a GAAP net loss of $2.63 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.
